

Improved homology-directed gene repair using the Alt-R™ CRISPR-Cas9 System

CRISPR-Cas9 genome editing reagents delivered as a ribonucleoprotein complex increase repair efficiency compared to plasmid-based delivery methods

Dr Eric Kmiec at the Gene Editing Institute, Helen F. Graham Cancer Center and Research Institute, Christiana Care Health System, compared the Alt-R CRISPR-Cas9 System ribonucleoprotein (RNP) to plasmid-based CRISPR-Cas9 tools for their ability to facilitate homology-directed repair of a mutated gene. His research group used a human colorectal carcinoma-derived cell line (HCT116), containing a single, stably incorporated eGFP with a nonsense, point mutation. In addition to the CRISPR-Cas9 components, a 72-nucleotide, single-stranded, donor oligo was used to correct the eGFP sequence to produce a functional eGFP protein for counting successful events by fluorescence-activated cell sorting (FACS). All components were delivered by electroporation. The researchers found that the RNP CRISPR-Cas9 approach doubled the correction efficiency in their experiments (Figure 1) and eliminated toxicity observed with the plasmid-based system.




Figure 1. Improved homology-directed repair by ribonucleoprotein delivery of CRISPR-Cas9 genome editing reagents. Optimization of gene editing was performed in an HCT116 cell line with an integrated, single copy of an eGFP mutant gene containing a nonsense mutation at position +67 (TAC →TAG). Alt-R™ CRISPR-Cas9 System components were assembled into an RNP to target the nonsense mutation site, as instructed (www.idtdna.com/CRISPR-Cas9). For comparison, a chimeric single-guide RNA was cloned into a pX330 backbone vector (Addgene) that also expresses a codon optimized SpCas9 (2C plasmid). A single-stranded 72 nt oligonucleotide was used as donor template for homology-directed repair of the nonsense mutation. CRISPR-Cas9 components and donor template were delivered into the cells using a Gene Pulser Xcell™ Electroporation System (Bio-Rad Laboratories). Cells were assayed for eGFP repair 72 hr after electroporation by using the Guava® easyCyte 5HT Benchtop Flow Cytometer (Millipore; green bars) and FACSAria™ II Flow Cytometer (BD Biosciences; blue bars) instruments. Error bars represent standard deviation.

// Having been in the field of gene editing for almost 20 years, the development and evolution of the CRISPR-Cas9 system has simply changed everything. However, the overexpression of the guide RNA and Cas9 components in transfected vectors creates a standard problem for most biomedical systems—an unhealthy and often deleterious environment inside the targeted cells. Fortunately, we were introduced to the Alt-R CRISPR-Cas9 System and RNP delivery method developed by IDT. Now, not only has the frequency of single-nucleotide repair improved significantly, but the cells maintain a high degree of viability and the capability to carry out metabolic processes, including cell division, in a normal fashion. //

Eric Kmiec, PhD

Director, Gene Editing Institute, Helen F. Graham Cancer Center
and Research Institute, Christiana Care Health System,
Wilmington, DE, USA

IDT recommends using Alt-R S.p. Cas9 Nuclease 3NLS combined with Alt-R CRISPR-Cas9 crRNA and tracrRNA to generate a ribonucleoprotein editing complex for high editing efficiency across most target sites. View the *Alt-R CRISPR-Cas9 User Guide for ribonucleoprotein transfections* for delivery of the RNP into your cell lines ([available at www.idtdna.com/CRISPR-Cas9](http://www.idtdna.com/CRISPR-Cas9)).

For Research Use Only. Not for use in diagnostic procedures.

©2017 Integrated DNA Technologies, Inc. All rights reserved. Trademarks contained herein are the property of Integrated DNA Technologies, Inc. or their respective owners. For specific trademark and licensing information, see www.idtdna.com/trademarks. CRS-10049-AN 02/17